Blog
RSS FeedPosted by Michael Wonder on 28 May 2018
Community voices important to PHARMAC
28 May 2018 - This year, PHARMAC is reviewing the way we seek and incorporate the consumer voice in our ...
Posted by Michael Wonder on 21 May 2018
August 2018 PBAC special meeting - invitation for submissions open and background paper available
21 May 2018 - PD-1 and PD-L1 checkpoint inhibitor immunotherapies: options for subsidy consideration for multiple cancer types. ...
Posted by Michael Wonder on 17 May 2018
Prescription for pharmacy talks: add consumers
17 May 2018 - The Consumers Health Forum will urge the government to ensure the next negotiations for the Community ...
Posted by Michael Wonder on 24 Apr 2018
Australia’s health panel: your chance to influence the health system
24 April 2018 - Australians will get a chance to have their say about the health system by joining a ...
Posted by Michael Wonder on 09 Apr 2018
Public hearing on 13 June 2018
9 April 2018 - Citizens to be consulted on quinolone and fluoroquinolone antibiotics. ...
Posted by Michael Wonder on 27 Mar 2018
Gene therapy: international regulatory and health technology assessment activities and reimbursement status
28 March 2018 - There is widespread variation in the definition of gene therapy used by international regulatory bodies and a ...
Posted by Michael Wonder on 27 Mar 2018
Health consumer choice drives better care
27 March 2018 - Giving people greater choice in human services including health would give consumers more control over their ...
Posted by Michael Wonder on 13 Mar 2018
ICER requests public comment on two draft scoping documents: treatments for high-risk prostate cancer and amyloidosis
12 March 2018 - The ICER has posted two draft scoping documents outlining planned reviews of 1) three anti-androgen therapies ...
Posted by Michael Wonder on 23 Feb 2018
Nusinersen stakeholder meeting outcome statement
23 February 2018 - The outcome statement for the nusinersen stakeholder meeting held on 18 January 2018 is now available. ...
Posted by Michael Wonder on 11 Dec 2017
Call for feedback: medicine for the management of rheumatoid arthritis
9 December 2017 - A draft report on medicine for the management of rheumatoid arthritis is now available for feedback from ...
Posted by Michael Wonder on 08 Dec 2017
Consumer outcome statement for the post-market review of PAH medicines
8 December 2017 - A consumer session was held with patients with PAH and their carers during the PHAA Members Carers ...
Posted by Michael Wonder on 08 Dec 2017
Post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis - stakeholder forum outcome
8 December 2017 - A stakeholder forum was held for the post-market review of the use of biologics in the ...
Posted by Michael Wonder on 12 Nov 2017
Evaluation of patient and public involvement initiatives in health technology assessment: a survey of international agencies
10 November 2017 - Although there is increased awareness of patient and public involvement among health technology assessment organisations, evaluations of ...
Posted by Michael Wonder on 26 Oct 2017
Exploration and preferential ranking of patient benefits of medical devices: a new and generic instrument for health economic assessments
25 October 2017 - For medical devices, benefits other than direct clinical effects may have a large impact on the patients’ ...
Posted by Michael Wonder on 26 Oct 2017
Taking patient heterogeneity and preferences into account in health technology assessments
25 October 2017 - The INTEGRATE-HTA project provided methodology to evaluate complex technologies. ...